Increased expression of A 6 B 4 integrin in several epithelial cancers promotes tumor progression; however, the mechanism underlying its transcriptional regulation remains unclear. Here, we show that depletion of homeodomaininteracting protein kinase 2 (HIPK2) activates B 4 transcription that results in a strong increase of B 4 -dependent mitogenactivated protein kinase and Akt phosphorylation, anchorageindependent growth, and invasion. In contrast, stabilization of HIPK2 represses B 4 expression in wild-type p53 (wtp53)-expressing cells but not in p53-null cells or cells expressing mutant p53, indicating that HIPK2 requires a wtp53 to inhibit B 4 transcription. Consistent with our in vitro findings, a strong correlation between B 4 overexpression and HIPK2 inactivation by cytoplasmic relocalization was observed in wtp53-expressing human breast carcinomas. Under loss of function of HIPK2 or p53, the p53 family members TAp63 and TAp73 strongly activate B 4 transcription. These data, by revealing that B 4 expression is transcriptionally repressed in tumors by HIPK2 and p53 to impair B 4 -dependent tumor progression, suggest that loss of p53 function favors the formation of coactivator complex with the TA members of the p53 family to allow B 4 transcription.
Introduction
Altered h 4 expression is found in several tumors of epithelial origin where the integrin activates signaling pathways that modulate cell proliferation and survival (1, 2) . a 6 h 4 integrin associates with ErbB2 in mammary cells and cooperates with ErbB2 to promote phosphatidylinositol 3-kinase-dependent invasion and survival (3, 4) . In MMTV-Neu mice, the introduction of a targeted deletion of the h 4 cytoplasmic domain revealed that h 4 integrin promotes mammary tumor progression by cooperating with ErbB-2 signaling (5). This is due, at least in part, to the integrin ability of regulating, at the translation level, the expression of the ErbB-3 receptor that results in an increase of ErbB2/ErbB3 heterodimerization and, consequently, in the activation of the phosphatidylinositol 3-kinase survival pathway (6) . In mammary tumors, in patients with low disease-free survival, a 6 h 4 expression is functionally associated with ErbB3, phosphorylated Akt, and estrogen receptor-h1 negativity (7) . h 4 expression was also shown to be strongly associated with mammary basal-like tumors and their aggressive behavior (8, 9) . In agreement with a functional role of increased a 6 h 4 expression in tumor progression, depletion of a 6 h 4 integrin inhibits tumor cell growth both in vitro and in vivo (10) (11) (12) and strongly reduces the activity of the phosphatidylinositol 3-kinase pathway, favoring responsiveness to tamoxifen treatment in MCF7 cells (11) .
The increase of a 6 h 4 expression in epithelial cancers and the peculiarity of its distribution have suggested that h 4 expression might be regulated, at least in part, at the transcriptional level (13) . In follicular and papillary thyroid carcinomas, a 6 h 4 integrin is transcriptionally activated on cell transformation (14) . In contrast, in skin basal cell carcinoma (15) and prostate cancers (16) , the expression of a 6 h 4 is reduced compared with normal tissues, further indicating a transcriptional regulation of h 4 in tumors.
Recently, the transcription factor p63 was shown to be a key regulator of the ITGB4 gene (the h 4 integrin subunit) transcription in mammary MCF10A cells (17) . In the present study, we show that homeodomain-interacting protein kinase 2 (HIPK2) controls h 4 integrin transcription. HIPK2 is a nuclear serine/threonine kinase originally identified as corepressor for homeodomain transcription factors (18) . It binds p53 regulating its localization, phosphorylation, acetylation, and transcriptional activity (19) (20) (21) . DNA damage-inducing agents, such as UV or Adriamycin, activate HIPK2 to induce p53-mediated apoptosis. This process is also associated with transcriptional repression or others genes, involved in tumor progression, such as galectin-3 (22) . HIPK2 can also physically interact with the p53 family members, p73 and p63, and modulate the activity of these proteins whose functions can be directly or indirectly related to apoptosis (23) .
Here, we show that HIPK2 requires wild-type p53 (wtp53) to repress h 4 transcription and that, in the absence of HIPK2 and/or p53 activity, h 4 transcription is strongly activated by TAp63 and TAp73. These findings were strongly supported by in vivo data. Indeed, analysis of 67 wtp53-carrying breast carcinomas revealed a strong correlation between h 4 overexpression and inactivation of HIPK2 by its cytoplasmic relocalization (24) , supporting the hypothesis that the loss of HIPK2 and/or p53 function can favor the up-regulation of h 4 integrin in human cancers.
GEO were provided by F. Guadagni, and LNCaP and PC3 were provided by A. Farsetti. RKO/shHIPK2 subclones were described previously (26) . For DNA damage, cells were treated with lethal (3 Amol/L) or sublethal (0.5 Ag/mL) doses of Adriamycin (Pharmacia) for 24 h or irradiated with 75 J/m 2 of UV light and collected at the indicate time points. Flow cytometry, soft agar, and invasion assays were done as described (7, 11) .
Transfections and plasmids. Vectors were transfected by Lipofectamine Plus (Invitrogen). pRC/CMV-h 4 vector was kindly provided by F. Giancotti. h 4 depletion was obtained by pSuper.retro vector containing h 4 -shRNA-specific sequence (6) . pcDNA3 carrying HA-tagged TAp73 (27) or myc-tagged TAp63 were kindly provided by S. Strano. pCMV-Flag-HIPK2 (19) and pSuperHIPK2 (28) were used to overexpress or deplete HIPK2. Transient HIPK2 depletion was obtained by HIPK2-specific Stealth RNAi (Invitrogen) with Lipofectamine RNAiMAX. p53 protein was overexpressed by pCAG3.1-wtp53 vector and silenced by pRetroSuper-wtp53 vector (28) .
The promoter-less luciferase reporter plasmid pGL-3 basic and pGL-3 L5.5K, carrying the 5 ¶-flanking region of the h 4 integrin gene (L5.5K fragment: -5197, +333), were kindly provided by T. Yamada and S. Hirohashi. Deletion mutants were generated by restriction endonucleases as follows: L2.2K (SacI, -1854, +333) and L0.7K (SmaI, -315, +333). Luciferase activity was determined with the dual-luciferase reporter assay system (Promega). Results were expressed as relative luciferase activity or folds of induction obtained by the ratio of the firefly/Renilla luminescence.
Western blot analysis and antibodies. Total cell extracts were prepared as described (7) . The following antibodies were employed: anti-h 4 439-9B and 450-11A monoclonal antibody (11); anti-HA (3F10; Calbiochem); antip53 (FL-393) and anti-mitogen-activated protein kinase (MAPK; Santa Cruz Biotechnology); anti-Akt (Cell Signaling); anti-HIPK2 antiserum (29) ; anti-atubulin (TU-01), actin (JLA20), and HSP70 (N27F3-4; Immunological Science); and FITC-and peroxidase-conjugated anti-IgG (Cappel).
Reverse transcription-PCR. Total RNA was prepared using RNazol B (Invitrogen). Reverse transcription-PCR analyses for h 4 and HIPK2 were done using the following primers: human h 4 5 ¶-GAATTCGTTCTACGCTCTCC-3 ¶ and 5 ¶-GAATTCTGAGAGATGTGGGC-3 ¶ and human HIPK2 5 ¶-AGTCCAC-GACTCCCCCTACT-3 ¶ and 5 ¶-ATGGTGGGAGTGATGTAGGC-3 ¶.
The housekeeping aldolase mRNA was used as an internal control (11) . Chromatin immunoprecipitation analysis. Chromatin immunoprecipitation was done as described (22) . Immunoprecipitations were carried out with anti-p53 (Ab-7), p63 monoclonal antibody (4A4), p73 antibody (C-20 and H-79), HADC1, and p300 antibody (Santa Cruz Biotechnology) and anti-H3-K9 and H4-K20 acetylated (Upstate Biotechnology).
The oligonucleotides used for detection of the p53RE-bearing fragments of the human ITGB4 gene are fragment p2 5 ¶-TGGGAGCTAAAAGG-CAAAGA-3 ¶ and 3 ¶-AGCACCAACAATGTGACCAA-5 ¶.
Patients and tissue specimens. The 67 stage I, IIa, and IIb wtp53 breast cancer patients included in this study have been already described (30) Tumors were staged according to the International Union Against Cancer tumor-node-metastasis system 2002 and graded according to Bloom and Richardson (31) . The study was reviewed and approved by the ethics committee of the Regina Elena Cancer Institute, and written informed consent was obtained from all patients.
Immunohistochemistry. Immunohistochemical analysis of h 4 integrin and HIPK2 was done as described (7, 24) . HIPK2 protein was considered overexpressed when >10% of the neoplastic cells presented a strong immunoreaction. h 4 expression was scored according to the following criteria: 0, no reaction; 1, low reaction (1-10% of positive cells; score +/++); and 2, high reaction (>10-50% of positive cells; score ++/+++).
Statistics. m 2 test was used to test the relationship between integrin h 4 overexpression and HIPK2 nuclear or cytoplasmic compartmentalization. P < 0.05 was considered statistically significant. The tests indicate how much of the association between h 4 and HIPK2 nuclear and cytoplasmic localization is accounted by linear trend. In vitro experiments were analyzed with Student's t test (*, P < 0.05; **, P < 0.01; ***, P < 0.001).
Results
B 4 transcription is induced by HIPK2 interference in B 4 -null RKO cells. The colon cancer RKO cells were shown previously to carry wtp53 and be negative for h 4 expression (32). In these cells, HIPK2 depletion causes a strong increase of in vivo tumor uptake and tumor growth (26) . Because expression of h 4 integrin is strictly related to tumor aggressiveness, we investigated whether the corepressor activity of HIPK2 was related to h 4 transcription. To test this hypothesis, we analyzed the expression of h 4 by reverse transcription-PCR and flow cytometry ( fluorescence-activated cell sorting) in RKO/mock and RKO/shHIPK2 cells. We found that h 4 transcript is absent in RKO/mock but strongly expressed in RKO/ shHIPK2 cells (Fig. 1A, left) , suggesting that HIPK2 corepresses h 4 transcription in these cells. De novo expression of h 4 protein in RKO/shHIPK2 cells was confirmed by fluorescence-activated cell sorting (Fig. 1A, right) . Regulation of h 4 transcription was further evaluated by testing the h 4 promoter activity by transfecting RKO/ mock and RKO/shHIPK2 with a vector carrying L5.5K fragment of the h 4 promoter. As shown in Fig. 1B , h 4 promoter activity was strongly increased on depletion of HIPK2 (P < 0.01, shHIPK2 versus mock RKO cells). This result was confirmed in LNCaP prostate cancer cells, another h 4 -negative cell line. The transient depletion of HIPK2 causes de novo expression of h 4 protein but, as soon as the HIPK2 interference is lost, LNCaP cells return to be negative for h 4 expression (Fig. 1C, left) . Comparable results were also obtained in MCF7 and LoVo cells silencing HIPK2 by the use of Stealth siRNA, with different HIPK2-interfering sequences (Fig. 1C, middle and right). The data support the results obtained in RKO cells and exclude the possibility of selection of secondary effects. In agreement with this, data from arrays revealed up-regulation of h 4 transcription in HIPK2-depleted cells. 5 Rescue of B 4 protein on HIPK2 interference increases MAPK and Akt phosphorylation, anchorage-independent growth, and invasion. We next analyzed the signaling pathways affected by the h 4 molecule. As shown in Fig. 2A , de novo expression of h 4 induces a strong activation of MAPK phosphorylation in RKO/ shHIPK2 compared with the basal level observed in RKO/mock Figure 2 . HIPK2 depletion activates h 4 -dependent, anchorage-independent growth and invasion. MAPK (A ) and Akt (B) phosphorylation levels of mock, shHIPK2, and shHIPK2/shh 4 RKO cells. C, the same cells were assayed for their ability to invade Matrigel. D, efficiency of anchorage-independent growth as reported previously (12, 16) . Results F SD were obtained from three independent experiments. Right, representative colony formations. Hrg b1, heregulin h1.
cells. Based on our previous results (6, 7), we confirmed that expression of h 4 integrin induces a strong increase of ErbB3 synthesis (Fig. 2B) , resulting in increase of Akt phosphorylation on heregulin h1 stimulation. The specificity of HIPK2-induced h 4 -dependent signaling was confirmed by the finding that transient h 4 interference in RKO/shHIPK2 cells inhibits the level of MAPK and Akt activation ( Fig. 2A and B) and causes a decrease of ErbB3 expression (Fig. 2B) . The activation of MAPK and phosphatidylinositol 3-kinase signaling pathways determines a strong increase of invasion and anchorageindependent growth of shHIPK2 cells compared with RKO/ mock cells (P < 0.001 and P < 0.05, respectively; Fig. 2C and D) . Depletion of h 4 in RKO/shHIPK2 cells abolishes the increment of anchorage-independent growth and invasion indicating that HIPK2 controls through h 4 -transcription cell growth and invasion (P < 0.001 and P < 0.05, respectively; Fig. 2C and D) . Representative soft-agar colony formation is shown in Fig. 2D (right) . B 4 transcriptional repression by HIPK2 requires the presence of wtp53. To investigate whether p53 is involved in HIPK2-mediated h 4 transcriptional regulation, we analyzed a panel of human cancer cell lines endogenously expressing h 4 integrin and carrying wild-type or mutated p53 or p53-null. The cells were treated either with UV or Adriamycin, and the levels of HIPK2, p53 and h 4 were evaluated by reverse transcription-PCR and Western blot in the presence of HIPK2 or on its interference. Adriamycin treatment abrogated h 4 expression at the RNA and protein levels in wtp53-expressing MCF7 cells but not on HIPK2 depletion (Fig. 3A,  left) as well as in RKO/shHIPK2 cells (Fig. 3A, right) . Comparable results were obtained by UV treatment of MCF7 and HCT116 cells (Fig. 3B) . In contrast, UV treatment did not affect h 4 expression in HT29 cells that express a mutated form of p53 (Fig. 3B, right) . In addition, HIPK2 overexpression down-regulated h 4 expression in wtp53 HCT116 cells but not in their p53-null derivatives (Fig. 3C , left and middle), indicating that HIPK2 requires a wtp53 protein to inhibit h 4 expression. These results were strongly supported by the finding that depletion of HIPK2 increased h 4 expression only in HCT116 cells but not in their p53-null derivatives (Fig. 3C, right) . In agreement, several colon cancer cells expressing mutated p53 (WiDr, HT29, SW480, and GEO) show high level of h 4 expression, whereas wtp53-carrying cells (MIP, DLD-1, and LoVo) show low level of h 4 . Consistent, prostate wtp53-carrying LNCaP and p53-null PC3 cells were negative and positive for h 4 expression, respectively (Fig. 3D, top) . The correlation between h 4 expression and p53 status was further confirmed by the basal transcriptional activity of h 4 promoter we found in the same cell lines (Fig. 3D, bottom) .
Integrin B 4 overexpression strongly associates with HIPK2 cytoplasmic relocalization in breast carcinomas. To evaluate whether the relationship between h 4 overexpression and HIPK2 functionality we defined in tumor cell lines can occur in vivo, integrin h 4 expression and HIPK2 nuclear and cytoplasmic compartmentalization were analyzed in 67 stage I and II wtp53-carrying breast cancer patients whose clinical characteristics have been described previously (30) . In these patients, it was shown previously that overexpression of high-mobility group A1 protein correlates with HIPK2 cytoplasmic localization and a low spontaneous apoptotic index (24) . Thus, we asked whether a similar correlation occurred between HIPK2 localization and h 4 overexpression. Among the tumors analyzed, h 4 exhibited a strong homogeneous immunoreaction when HIPK2 was relocalized in the cytoplasm (62.5%). In contrast, when the tumors were h 4 -negative (73.3%), HIPK2 was localized in the nucleus (Fig. 4A) . Representative immunohistochemically positive and negative cases for HIPK2 and h 4 are shown in Fig. 4B . We also observed that HIPK2 was present in 39 (58.2%) tumors, with a cytoplasmic pattern of reactivity in 24 (35.8%) patients and a nuclear pattern in 15 (22.4%) patients. In the integrin h 4 -positive samples, HIPK2 showed a cytoplasmic pattern in 62.5% of the cases and a nuclear one in 26.7% (P = 0.03, m 2 test; Supplementary Table S1 ). In tumor cells, the p53 family members divergently regulate B 4 transcription. To investigate in detail the role of p53 in the regulation of h 4 transcription, we overexpressed HIPK2 and p53 in LoVo colon cancer cells that endogenously express low level of h 4 integrin. Overexpression of wtp53 inhibits, although to a lesser extent than HIPK2, the transcriptional activity of the h 4 promoter (P < 0.01; Fig. 5A ). The h 4 promoter region cloned into the L5.5K construct includes three putative p53-binding elements: p1 (-3141, -3117), p2 (-1088, -1064), and p3 (-107, -84). To assess their participation in the p53-dependent repression of h 4 transcription, we generated L2.2K and 0.7K deletion mutants, lacking one (p1) and two (p1 + p2) p53-responsive elements, respectively (Fig. 5B,  top) . Overexpression of the three reporter constructs in LoVo cells revealed that the basal level of h 4 promoter activity is enhanced when the cells were transfected with L2.2K construct (P < 0.05) and further activated in the absence of two p53-responsive elements (L0.7K; P < 0.01; Fig. 5B ). However, the concomitant expression of p53 down-regulates the activity of all three h 4 constructs (P < 0.05), indicating that p53 can use each of the three p53-responsive elements to negatively regulate h 4 transcription.
It has been shown previously that p63, one of the p53 family members, activates h 4 transcription in MCF10A normal epithelial cells (17) . Both p63 and p73 are known to bind to canonical p53 DNA-binding sites and transactivate several p53-responsive promoters (33) . However, novel target genes that are differentially regulated by various p53 family members were recently identified (34) . To analyze the involvement of p63 and p73 in the regulation of h 4 transcription in tumors, we cotransfected the L5.5K reporter construct with TAp63 or TAp73 in RKO/mock and RKO/ shHIPK2 cells. Overexpression of either TAp63 or TAp73 activates h 4 transcription in RKO/mock cells and even strongly in RKO/ shHIPK2 cells (P < 0.01, and P < 0.001, respectively; Fig. 5C ). Re-expression of HIPK2 in RKO/shHIPK2 significantly reduces (P < 0.01) TAp63 and TAp73-dependent activation of h 4 transcription, indicating that HIPK2 contrasts the transcriptional activity of p63 and p73 on h 4 promoter (Fig. 5C ). In addition, TAp73 overexpression in RKO and LoVo cells on p53 interference further increased h 4 transcription (Fig. 5D, left and middle) . These results were consistent with the increase of the endogenous h 4 protein we found in the p53-depleted LoVo cells (Fig. 5D, right) . Taken together, these data suggest that HIPK2 and p53 inhibit h 4 transcription counteracting the transcriptional activity of TAp63 and TAp73 on the h 4 promoter. B 4 transcriptional modulation by HIPK2 and p53 family members involves HDAC and p300. HIPK2 can interact with homeobox factors forming corepressor complexes that contain histone deacetylases (35, 36) . To verify this corepressor activity on the h 4 promoter, we performed chromatin immunoprecipitation assays in RKO/mock and RKO/shHIPK2 cells by amplifying the p2 region h 4 promoter as indicated in the cartoon (Fig. 6A) . In this region, histones H3 and H4 are acetylated in RKO/shHIPK2 cells but not in RKO/mock cells (Fig. 6B, top left) . In agreement, the HDAC1 deacetylase, which can form corepressor complex with HIPK2 reinforcing its corepressor activity (35) , is present on the h 4 promoter only in the HIPK2 positive RKO/mock cells (Fig. 6B, top  right) . Given that the histone acetyltransferase p300/CBP can mediate p63-and p73-dependent transcription (37), we evaluated the presence of p300 on the h 4 promoter and found that it was absent in HIPK2 expressing cells but recruited on HIPK2 interference (Fig. 6B, top right) . In addition, p53 is present on the h 4 promoter in RKO/mock cells, whereas HIPK2 depletion strongly reduces the amount of p53 bound to the promoter (Fig. 6B,  bottom) . By contrast, a greater amount of p63 and p73 is detectable in the h 4 promoter in RKO/shHIPK2 cells compared with RKO/ mock cells (Fig. 6B, bottom) . These results were confirmed in LoVo cells by transient HIPK2 depletion by siRNA (Fig. 6B, bottom) . Interestingly, overexpression of TAp73 in mutated p53-carrying HT29 or p53-null HCT116 cells strongly enhances the activity of h 4 promoter (P < 0.01; Fig. 6C ). As expected, both p63 and p73 were present on the h 4 promoter, whereas p53 was not (Fig. 6D) .
Overall, these data indicate that although the detailed molecular mechanism of h 4 transcription by p53 family members is not yet clear, p53 and its family members directly interact with the h 4 promoter to repress or activate, respectively, h 4 transcription. In addition, although both p63 and p73 activate h 4 transcription, our results also indicate that TAp73 poses the stronger activity.
Discussion
We have identified a mechanism by which the h 4 integrin subunit is regulated at the transcriptional level during tumor progression. In normal epithelial tissue, the presence of a 6 h 4 integrin is restricted to the basal layer of the cells where it is required for hemidesmosome formation, cell adhesion, and cell survival (38) . Many epithelial tumors lack the hemidesmosome and a 6 h 4 expression is strongly increased and redistributed on the entire cell surface, indicating that, in these tumors, the integrin plays different role besides adhesion (39) . These and other studies have suggested the existence of different transcriptional regulation of a 6 h 4 integrin during tumor progression . Our study is the first one showing that a 6 h 4 integrin is regulated in epithelial tumors at the transcriptional levels by HIPK2 and p53 that contributing to its regulation control h 4 -induced tumor progression. This mechanism involves a functional pathway that links HIPK2 to the ability of p53 to suppress the survival function induced by h 4 integrin. We have defined a critical role for HIPK2 in the regulation of h 4 integrin expression. Knockdown of endogenous HIPK2 induced de novo expression of h 4 in RKO colon cancer cells and increased h 4 -dependent signaling and tumor progression. These results are in strong agreement with previous findings showing that depletion of HIPK2 in RKO cells enhances in vivo tumorigenicity and tumor uptake (26) .
However, HIPK2 acts as corepressor in concert with transcription factors, and among them, the p53 tumor suppressor represents one major HIPK2 target (36) . In response to genotoxic stress, HIPK2 binds and activates p53 to induce apoptosis by activation of a large number of proapoptotic factors and the repression of antiapoptotic factors (36) .
In contrast to p53, h 4 is considered a prosurvival factor and it is widely assumed that the distinct signaling properties of the a 6 h 4 integrin account for its ability to enhance functions such as invasion and resistance to apoptotic stimuli (11, 12) . Further, a 6 h 4 expression is strictly correlated with tumor progression (39) leading to hypothesize that p53 could control h 4 transcription in the early phases of transformation or until p53 is functionally active. Indeed, our results support the hypothesis that a transcriptionally active p53 controls h 4 expression maintaining its level low in cancer cells. Microarray analysis revealed that RITA treatment in wtp53-carrying HCT116 cells activating p53 apoptotic function causes a down-regulation of h 4 mRNA level, further supporting our finding that wtp53 controls h 4 expression level (40) . 6 An important observation is that p63 regulates adhesion program and cell survival in normal mammary epithelial cells and that the h 4 gene is a direct target of p63 in these cells (17) . These observations had added new highlights to the mechanism that regulates h 4 expression in normal epithelial tissues and suggested the possibility that others p53 family members participate to the regulation of its 6 Galina Selivanova, personal communication. transcription. In line with this idea are our findings showing that overexpression of TAp63 or TAp73 strongly enhances h 4 transcription.
Although the p53-independent functions of p63 and p73 during development are clear, their role in tumorigenesis is less evident (33) . In this respect, there is now increasing evidence supporting their participation to tumor formation and progression (33, 41) . The expression of p63 and p73 reported in these studies strongly correlates with the expression of h 4 integrin previously analyzed in the same types of tumor (2, 7, 9, 42) . Our results are apparently in contrast with recent finding showing that TAp73 knockout mice show genetic instability associated with enhanced aneuploidy and increased incidence of spontaneous tumors, indicating that TAp73 possess the tumor-suppressive ability (43) . However, the tumor phenotype shown in TAp73 -/-mice occurs in a wtp53 background and it has been shown previously that the absence of p63 or p73 impairs the induction of p53-dependent apoptosis in response to DNA damage (44) . These data indicate a specific role of p63 and p73 molecules in potentiating the apoptotic function of p53 and suggest a different role for these molecules in the loss of function of p53. We also cannot exclude that in the absence of HIPK2 or p53 function a different balance among the p53 family members might generate the formation of different transcription complexes that exert opposite effects on the same promoter as previously hypothesized for the p53 family members (33) . However, both TAp63 and TAp73 belong to a complex family of factors with opposite functions, the relationships of which need further studies to understand their role during tumor progression.
Eventually, our results are strongly supported by the in vivo data showing a statistically significant correlation between h 4 overexpression and HIPK2 relocalization to the cytoplasm and are in agreement with recent finding showing that the stable depletion of HIPK2 leads to wtp53 misfolding causing a down-regulation of its transcriptional activity (45) .
In summary, although the detailed molecular mechanisms need to be further clarified, our data indicate that HIPK2 and wtp53 corepress h 4 promoter impairing h 4 -inducing tumor progression and that, in the absence of HIPK2 or when p53 becomes transcriptionally inactive, the TA members of the p53 family become able to transcribe the h 4 gene.
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